AML-001
Acute Myeloid Leukemia · FLT3/IDH/NPM1 Engine · VIZASL v1
MEBICAL · EOSE Fleet · Day 95 · Real data · Cited · γ₁-anchored
MEBICAL · HAEMATOLOGY← RESEARCH
Acute Myeloid Leukemia
γ₁ floor anchor
PHASES
SORRIES
BM
NPs
Molecular Engine + Treatment
7+3 Induction PROVEN
Cytarabine 7d + dauno 3d. CR 60-80% fit. Since 1973.
Fernandez 2009 NEJM
Midostaurin FLT3i RATIFY PROVEN
FLT3-ITD/TKD: +midostaurin. 4yr OS 51.4% vs 44.3%.
Stone 2017 NEJM n=717
Enasidenib IDH2i PROVEN
IDH2-mutant. CR 19% mono. Diff syndrome 14%.
DiNardo 2018 NEJM AG221
Venetoclax+AZA VIALE-A PROVEN
Elderly unfit. CR+CRi 66% vs 28%. OS 14.7 vs 9.6mo.
DiNardo 2020 NEJM n=431
Menin Inhibitor Revumenib OPEN
KMT2A-r + NPM1. CR 53% r/r. FDA Oct 2023 KMT2A-r.
Issa 2023 Nature
Open Sorries — Click to Expand
S-1 SORRY-1 · No Single Driver
S-2 SORRY-2 · CAR-T Fratricide
S-3 SORRY-3 · FLT3 Resistance
S-4 SORRY-4 · TP53 AML Untreatable
S-5 SORRY-5 · MRD Not Standardized
Biomarkers + Signal
See Phases tab for molecular classification details. Key biomarkers noted in phase gates above.
Novel Patterns
Emerging therapies and patterns logged in PEMCLAU v11. See GREYBACK yang case corpus for yin/yang attack-defense mapping.
AML-001 · HETEROGENEOUS FORTRESS · CAR-T FRATRICIDE UNSOLVED · γ₁ = 14.134725141734693
γ₁ = 14.134725141734693